Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
The dosage of sparsentan is individualized; please use it in accordance with your doctor’s instructions or the information on the drug label.What are the daily precautions for spar···【more】
Article source：Captain MedicineRelease date：2026-02-09Recommended：52
Sparsentan is indicated for slowing the decline in renal function in adult patients with primary immunoglobulin A nephropathy (IgAN) who are at risk of disease progression.What Pre···【more】
Article source：Captain MedicineRelease date：2026-02-09Recommended：50
Belzutifan produced by Lucius Pharmaceuticals is a bioequivalent generic drug with the same mechanism of action as the marketed drug. It is indicated for the treatment of diseases ···【more】
Article source：Captain MedicineRelease date：2026-02-06Recommended：44
The version of belzutifan produced by Lucius Pharmaceuticals is a more cost-effective generic drug, designed to provide renal cell carcinoma patients with the same active ingredien···【more】
Article source：Captain MedicineRelease date：2026-02-06Recommended：47
Belzutifan is an oral targeted drug of the hypoxia-inducible factor-2α (HIF-2α) inhibitor class, mainly indicated for the treatment of various tumors associated with von Hippel-Lin···【more】
Article source：Captain MedicineRelease date：2026-02-06Recommended：57
Belzutifan is a hypoxia-inducible factor (HIF) inhibitor. It exerts its effect by blocking a protein known as HIF-2α.Is Belzutifan associated with severe side effects?The severe si···【more】
Article source：Captain MedicineRelease date：2026-02-06Recommended：52
Doctors should conduct regular follow-ups to evaluate the efficacy of the medication, and adverse reactions may need to be monitored through blood and urine tests.Precautions for U···【more】
Article source：Captain MedicineRelease date：2026-02-05Recommended：32
After administration, necessary therapeutic effects may occur, and adverse reactions may also be triggered. Not all adverse reactions will manifest. If any adverse reaction occurs,···【more】
Article source：Captain MedicineRelease date：2026-02-05Recommended：37
Some medications are absolutely contraindicated for combined use. For other medications, even if drug interactions may occur, they can still be used under the guidance of a physici···【more】
Article source：Captain MedicineRelease date：2026-02-05Recommended：43
Cabozantinib is a non-chemotherapy prescription medication classified as a tyrosine kinase inhibitor (TKI). It is administered as a tablet, taken once daily, or as directed by a he···【more】
Article source：Captain MedicineRelease date：2026-02-05Recommended：45
Patients should take pirfenidone with meals at a fixed time every day to reduce the incidence of adverse reactions such as nausea and dizziness. For patients taking strong or moder···【more】
Article source：Captain MedicineRelease date：2026-02-04Recommended：64
The most common side effects of pirfenidone include upper respiratory tract infection, fatigue, headache, dizziness, decreased appetite, sinusitis, insomnia, and weight loss.Are th···【more】
Article source：Captain MedicineRelease date：2026-02-04Recommended：44
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：1592025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：3992024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：1532025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：1732025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：1532025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：1872025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：1682025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：1642025-27-11
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
